Chronic obstructive airways disease (COPD) and asthma are major causes of morbidity around the world. This review examines the evidence on the effectiveness of tiotropium as a treatment for COPD and asthma. It discusses the role of acetylcholine in airway physiology and the effects of muscarinic antagonism on airways smooth muscle, mucous secretion and inflammation. In COPD, tiotropium increases forced expiratory volume in 1 second (FEV 1 ) and reduces hyperinflation; it improves breathlessness, exercise capacity and health status, and it reduces exacerbation rates. Tiotropium also reduces the rate of decline in FEV 1 over 4 years in patients with an FEV 1 over 50% predicted. In asthma, when added to inhaled steroids alone or in combination with long-acting beta agonists, tiotropium improves lung function, improves asthma control and reduces exacerbations. These effects have been seen in children, adolescents and adults with asthma. Tiotropium is well tolerated, with a low incidence of adverse events. (BRN Rev. 2018;4:135-52)
IntroductIon
Asthma and chronic obstructive pulmonary disease (COPD) are both common chronic diseases characterised by airflow obstruction. COPD is now the third most common cause of death worldwide 1 and the Global Burden of Disease project estimated that COPD affected 174 million people worldwide in 2015 causing 3.2 million deaths, an increase of 11.6% compared with 1990. Asthma affected 358 million people worldwide and caused 400,000 deaths, a decrease of 26.7% from 1990 2 .
Long-acting bronchodilators are the mainstay of treatment for COPD 3 and now play an important role alongside inhaled corticosteroids (ICS) in reducing symptoms in patients with uncontrolled asthma 4 . Tiotropium bromide was the first long-acting muscarinic antagonist (LAMA) to be approved for maintenance treatment of COPD. It has been available since 2002, and it is widely prescribed in over 110 countries worldwide with patient experience of over 25 million patient-years 5 . It is available in two formulations: dry powder (18 µg once daily) delivered via the HandiHaler inhaler, and aqueous solution (5 µg, two puffs 2.5 µg once daily) delivered via the Respimat Soft Mist Inhaler. Since 2014, tiotropium in the Respimat has also been licensed in the European Union (EU) for addon maintenance treatment of adults with symptomatic asthma and it is still the only LAMA to have this indication. This review examines the evidence on the efficacy and safety of tiotropium in COPD and asthma, considers this in the context of the evidence on the efficacy of other LAMAs in COPD and briefly examines the efficacy of tiotropium when combined with the long-acting β2-agonists (LABA) olodaterol.
Acetylcholine is synthesized from choline and acetyl coenzyme A mainly by the enzyme choline acetyltransferase which is expressed parasympathetic neuron in the airways but also in airway epithelial cells [6] [7] [8] . Human airways contain M1, M2, and M3 muscarinic receptors. M3 receptors mediate acetylcholine's effects on airway smooth muscle tone and mucous secretion from mucosal glands. M2 receptors have an inhibited auto-regulatory effect on the release of acetylcholine from both pre-and post-ganglionic nerve terminals but are also widely expressed by other cells such as fibroblasts and smooth muscle cells 9 . Non-neuronal acetylcholine released from epithelial cells acts as a paracrine/autocrine hormone maintaining cellular homeostasis and epithelial repair, regulating ciliary activity and mucociliary clearance and modulating the activity of inflammatory cells promoting their survival and cytokine release 7, 10 .
Tiotropium antagonises all three muscarinic receptors present in the airways, but it has a higher selectivity for M3 receptors than for M2 receptors, and it dissociates more slowly from M3 receptors than from M2 receptors giving it its long duration of action 11 .
M3 antagonism leads to airway smooth muscle relaxation and a reduction in mucus secretion, which is important, as hypersecretion may contribute to airflow limitation in asthma and COPD, and it is a risk factor for accelerated loss of lung function and exacerbations 12 . Animal studies have suggested tiotropium might improve airflow limitation by reducing airway mucus as well as its effects on smooth muscle 13 , and in patients with COPD, tiotropium was associated with a reduction in sputum volume 14 .
Both asthma and COPD are characterised by chronic inflammation and structural changes to the airways, although the underlying inflammatory processes differ between each disease 15 . Inflammation is an important therapeutic target for these diseases and in invitro and in animal models, tiotropium also appears to have anti-inflammatory properties due to M3 antagonism. In animal models pretreatment with tiotropium reduces eosinophilic inflammation in response to allergen exposure and partly prevents aspects of airway remodelling, inhibiting mucus gland hypertrophy and decreasing the number of MUC5AC-positive goblet cells, as well as reducing airway smooth muscle thickening [13] [14] [15] [16] . In animal models, tiotropium also inhibits neutrophil chemotactic activity, and decreases levels of cytokines (interleukin [IL]-4, IL-5, IL-13 & tumour necrosis factor alpha [TNF-α]) and leukotriene B4 in bronchoalveolar lavage fluid 17, 18 as well as inhibiting airway remodelling and pulmonary inflammation in a guinea pig model of COPD 18 .
Tiotropium may also have an indirect effect on inflammation in COPD through the suppression of repeated airway smooth muscle contraction, which reduces the inflammatory activity 9, 11 . In humans, tiotropium attenuates reactive oxygen species (superoxide anions) and leukotriene B4 production by peripheral blood neutrophils obtained from patients with COPD 18 .
clInIcAl effects of tIotropIum
In copd
The goal of COPD therapy is to obtain improve symptoms, exercise capacity and quality of life as well as minimising or preventing exacerbations, with minimal adverse events 3 . Tiotropium is widely used around the world to help deliver these goals. There is now experience of over 50 million patient-years of treatment 19 , including more than 2.5 million patient-years' experience with the Respimat 20 . Its use is supported by evidence from over 200 clinical trials and of many these trials include patients typical of those seen in primary care 21, 22 . Populations studied have included patients with mild to very severe airflow obstruction 22 , patients naïve to maintenance therapy 23, 24 , patients with common and relevant comorbidities, such as cardiovascular disease 22, [25] [26] [27] as well those with mild-to-moderate renal impairment 22 .
As well as the individual clinical trials, a number of systematic reviews with meta-regression analysis of pooled data have summarised the efficacy of tiotropium in patients with COPD 19, [28] [29] [30] [31] [32] [33] [34] as well as its safety 35, 36 . This review will not duplicate these reviews but will highlight the main findings.
Randomised trials have demonstrated lung function improvements with tiotropium versus placebo and active comparators. Lung function improvement is seen in patients with all levels of spirometric impairment and in all Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups 20, [37] [38] [39] . Whether administered in the HandiHaler or Respimat device tiotropium results in similar spirometric improvements 40 . The magnitude of the effect of tiotropium on FEV 1 (whether peak or trough) compared to placebo or other bronchodilators is remarkably consistent despite differences in the characteristics of the patients studied. of the patients included, concomitant and prior use of maintenance therapy, age and whether the Handihaler or Respimat soft mist inhaler were used to deliver the tiotropium. The details of the studies are listed in table 1.
As well as the changes in spirometry, tiotropium produces sustained reductions of lung hyperinflation at rest and during exercise 41 that lead to improvements in both exertional dyspnoea and exercise endurance as a result of the improved ability to increase tidal volume (Fig. 2) .
Among the many trials examining the efficacy of tiotropium, the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study stands out as it studied the effects compared to placebo against a background of usual therapy including LABA and ICS in nearly six thousand patients over 4 years 37 . There were improvements in trough FEV 1 when tiotropium was added of between 87 to 103 ml pre-bronchodilator and between 47 to 65 ml post-bronchodilator group and these improvements were maintained over four years. Improvements in FEV 1 were observed across the spectrum of disease in GOLD Stages 2-4 37 and GOLD 2011 Groups A-D COPD 38 and were similar in current and ex-smokers 42 .
In the UPLIFT study the primary endpoint, the rate of decline in lung function, was not significantly different between patients treated with tiotropium and those receiving standard C a s a b u r i e t a l . 1 1 6 D o n o h u e e t a l . 4 4 C h a n e t a l . 1 1 7 T
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As well as trials comparing tiotropium to placebo there have been studies comparing tiotropium to other long acting bronchodilators. These have shown greater FEV 1 improvements compared to twice-daily salmeterol 44 and non-inferiority to once-daily indacaterol 45 . Comparisons versus other LAMAs in patients with moderate-to-severe COPD have generally shown similar effects on lung function [46] [47] [48] , although one study showed significantly greater improvements with umeclidinium versus tiotropium 12-24 hours post-dose 49 .
Tiotropium consistently improves symptoms and health status compared with placebo (for a comprehensive review of studies, see Kaplan et al 50 .) Figure 3 shows the effect of tiotropium on health status as measured using the St Georges Respiratory Questionnaire (SGRQ) compared 
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with placebo across eight studies, which again varied in the severity of airflow obstruction and GOLD group of the patients included, concomitant and prior use of maintenance therapy, age and whether the Handihaler or Respimat soft mist inhaler were used to deliver the tiotropium. The details of the studies are listed in table 2. The magnitude of the mean effect is generally less than the 4 units considered the minimum clinically important difference, but the proportion of patients achieving a 4-unit change was significantly higher in all cases with tiotropium ( Fig. 4 and Table 2 ).
In the UPLIFT study SGRQ was significantly improved by tiotropium compared with standard maintenance therapy on a background of standard care throughout the 4-year study period 37 , including in GOLD 2 patients 43 , those who were naïve to maintenance therapy (i.e. not receiving LABA, ICS, theophyllines or anticholinergics) at baseline 23 and those under the age of 50 51 . Figure 5 shows the effect of tiotropium on breathlessness measured using the transitional dyspnoea index (TDI) compared to placebo in the four trials which have examined this. There is less heterogeneity in the characteristics and patients studied in these trials, although there is some variation in the concomitant and prior use of maintenance therapy and both the Handihaler or Respimat soft mist inhaler were used to deliver the tiotropium. The details of the studies are listed in table 3. In each case the magnitude of the mean effect reaches or exceeds the 1-unit change considered the minimum clinically important difference. C a s a b u r i e t a l . 1 1 6 C h a n e t a l . 1 1 7 T
m a i n t e n a n c e n a ï v e U P L I F T -a g e ≤ 5 0 y r s B a t e m a n e t a l . 1 2 6 S M I B a t e m a n e t a l . 1 2 7 S M I B a t e m a n e t a l . 1 As well as improving lung function and health status and reducing breathlessness, tiotropium reduces COPD exacerbation rates in patients with all disease severities and comorbid risk factors. The effects on all exacerbations and specifically on hospitalised exacerbations have been comprehensively reviewed 29, 52 .
Overall tiotropium reduced the rate of exacerbations by between 14% and 52% depending on the population studied, what concomitant therapy was allowed and how exacerbations were recorded 29 . Evidence suggests that the effect is not simply due to sustained bronchodilation 29 . Potential mechanisms that may contribute to the preventive effects of tiotropium on COPD exacerbations are a reduction in the inflammatory stimulus repeated hyperinflation and deflation 53 , in a similar way to lung volume reduction surgery 54 , re-setting the threshold of 115 Casaburi et al. 116 Chan et al. 117 TIPHON 118 Cooper et al. 63 UPLIFT 37 Bateman SMI et al. 126 Bateman SMI et al. 126 Bateman et al. 127 Non LABA users SMI Bateman LABA et al. 127 users SMI C a s a b u r i e t a l . 1 1 6 C h a n e t a l . 1 1 7 B a t e m a n S M I e t a l . 1 2 6 Figure 5. Mean effect of tiotropium on transitional dyspnoea index (TDI) (± 95% CI) compared to placebo. For details of the studies, including inclusion criteria and permitted medications see table 3 . TDI: transitional dyspnoea index. 55 and suppression of acetylcholine-mediated inflammatory responses 56 .
In UPLIFT, tiotropium significantly delayed time to first exacerbation and first severe (hospitalised) exacerbation and reduced the number of exacerbations by 14% over 4 years versus standard respiratory therapy (p < 0.001) 37 . In a post-hoc analysis exacerbation risk was reduced with tiotropium across all GOLD stages 38 .
Studies have shown that tiotropium is significantly more effective at reducing exacerbations than either once or twice daily LABAs 29, 45, 57, 58 . The Investigation New Standards For Prophylaxis In Reduction Of Exacerbations (INSPIRE) study showed tiotropium had a similar effect on exacerbation rate to salmeterol/fluticasone, but patients treated with salmeterol/fluticasone had an increased incidence of pneumonia (8% versus 4% with tiotropium; p = 0.008) 59 .
The effect of tiotropium on exacerbations is similar whether the Respimat or HandiHaler devices are used 40 and the reduction in exacerbations provided by tiotropium may additionally have beneficial effects on cardiovascular disease and mortality as well as on COPD itself 60 .
The effects of tiotropium on lung function lead to an improvement in exercise capacity endurance, particularly when combined with pulmonary rehabilitation 4, [61] [62] [63] [64] .
Glycopyrronium bromide, aclidinium and umeclidinium are also LAMAs licensed for once or twice daily use in COPD. They each have data showing effects on lung function, health status, breathlessness and exacerbations compared to placebo 65, 66 .
The efficacy of twice-daily (bid) aclidinium bromide has been examined in 12 placebo randomised controlled trials lasting between 4 and 52 weeks. In a meta-analysis of these studies, aclidinium resulted in a significantly greater improvement in pre-dose FEV 1 30 . The GLOW5 trial, a 12-week blinded, double-dummy study comparing glycopyrronium with tiotropium, showed no difference between the two LAMAs in their effect on trough FEV 1 , TDI and SGRQ 48 . The study was too short to examine any difference in the effect on exacerbations.
Despite the effectiveness of tiotropium and other LAMAs, a significant proportion of patients remain breathless despite treatment with long-acting bronchodilator monotherapy 69 . GOLD recommends that for such patients, therapy should be escalated to dual therapy using two bronchodilators with different mechanisms of action 3 . For such patients, tiotropium is now available in combination with the new LABA olodaterol in the Respimat and a large phase III clinical trial programme of over 8000 patients 70, 71 has shown significant improvements in lung function compared to monotherapy 72 , irrespective of whether patients received prior LAMA or LABA maintenance treatment [73] [74] [75] . Other effects of the combination include reduced breathlessness and reduced rescue medication, as well as improvement in quality of life and exercise endurance 73, 75 , with the combination having a similar safety profile similar to the monotherapy components 73 .
Dual bronchodilator therapy is recommended by GOLD as the preferred choice for patients in Group D (i.e. higher levels of symptoms and higher risk of exacerbations) 3 . Escalation to triple therapy with LABA, LAMA and ICS is recommended if patients continue to exacerbate, but de-escalation by withdrawing ICS from triple therapy is also recommended as dual bronchodilator therapy can be as effective as triple therapy in preventing exacerbations. The Withdrawal Of Inhaled Glucocorticoids And Exacerbations of COPD (WISDOM) trial showed that withdrawal of the fluticasone in three steps over a 12-week period from triple therapy consisting of tiotropium (18 μg once daily), salmeterol (50 μg twice daily), and fluticasone propionate (500 μg twice daily) did not result in an increase rate of exacerbations 76 . Withdrawal of fluticasone did lead to a mean fall in FEV 1 of 38 ml after 18 weeks and 43 ml after 52 weeks, but there was no significant effect on modified Medical Research Council dyspnoea (mMRC) scores. There was an increased SGRQ score (i.e. worsening) of 0.55 points in the glucocorticoid-withdrawal group and a reduction of 0.42 points in the glucocorticoid-continuation group at week 27 (p = 0.08) and an increase of 1.15 and a decrease of 0.07, respectively, at week 52 (p = 0.047). The patients studied had an FEV 1 < 50% predicted and had had at least one exacerbation in the previous 12 months; they were all treated with triple therapy for 6 weeks BARCELONA RESPIRATORY NETWORK before the ICS withdrawal began, but only 39% of them had been on triple therapy prior to enrolment. In total 47% had been on a LAMA, 65% on a LABA and 70% on an ICS. In this population, dual bronchodilator therapy with tiotropium and salmeterol facilitated ICS withdrawal without increasing the risk of exacerbations, but a key question is whether there are sub-groups of patients who do better if maintained on ICS.
A post hoc analysis of the WISDOM study has shown that patients with a history of two or more exacerbations per year plus an eosinophil count ≥ 300 cells/ml have a lower risk of exacerbation if continued on ICS 77 .
clInIcAl effects of tIotropIum In AsthmA
Despite major advances in the management of asthma many patients, including children and adolescents remain uncontrolled and remain at risk of exacerbations [78] [79] [80] . LABA/ICS can achieve well-controlled asthma in around 70% of patients but not all 81 . Anticholinergic bronchodilators are the oldest documented therapy for asthma 82 .
The effects of tiotropium in asthma were first explored over 20 years ago when the sustained bronchodilator effects and protective effects against methacholine challenge were shown 83 .
More recently, the National Heart, Lung, and Blood Institute Asthma Clinical Research Network (ACRN) in the United States (US) undertook a study to investigate the effects of adding tiotropium to an inhaled glucocorticoid, compared to doubling of the dose of the inhaled glucocorticoid or adding the LABA salmeterol 84 . The effects of tiotropium administered via the Respimat in asthma have now been studied in an extensive clinical trial programme including over 6000 patients, including children, adolescents and adults with uncontrolled mild to moderate and severe asthma [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] . The findings supported of the individual studies have been supported by systematic reviews and meta-analyses [99] [100] [101] . The addition of tiotropium to ICS only, or ICS plus LABA results in statistically and clinically significant improvements in lung function, clinically significant reductions in exacerbation risk and improved asthma control 102 .
In the two PrimoTinA-asthma studies 5 μg tiotropium administered via the Respimat was added to therapy with LABA and ICS (≥ 800 μg of budesonide or the equivalent) in people with uncontrolled asthma (ACQ ≥ 1.5) 90 . Two of the co-primary end points were changes in peak FEV 1 (within 3 hours of administration) and trough FEV 1 at 24 weeks. Tiotropium resulted in an increase in peak FEV 1 (0-3 h) of 86 ml (95% CI: 20, 152) in trial 1 and 154 ml (95% CI: 91, 217) in trial 2 and an increase in trough FEV 1 of 88 ml (95% CI: 27, 149) in trial 1 and 111 ml (95% CI: 53, 169) in trial 2. In a pre-specified pooled analysis of the two trials there was a 21% reduction in the risk of having an exacerbation in patients treated with tiotropium (HR, 0.79, 95% CI: 0.62, 1.00). This was the third co-primary end point.
After 48 weeks tiotropium resulted in an increase in peak FEV 1 (0-3h) of 73 ml (95% CI: 5, 140) in trial 1 and 152 ml (95% CI: 87, 217)
in trial 2. The changes in trough FEV 1 after 48 weeks were 42 ml (95% CI: -21, 104) in trial 1 and 92 ml (95% CI: 32, 151) in trial 2. Improvements in asthma control and quality of life were also observed in both trials with marked improvements in the placebo groups particularly in trial 1. At week 24, the mean difference in ACQ-7 scores and Asthma Quality Of Life Questionnaire (AQLQ) score between groups was only statistically significant in trial 2 but did not exceed the minimal clinically important differences for the ACQ-7 of 0.5 or AQLQ of 0.5.
Pre-specified post hoc subgroup analyses of the PrimoTinA-asthma trials showed that the improvements in peak FEV 1 with tiotropium tended to be larger in patients with a lower FEV 1 and in ex-smokers, but were not related to level of reversibility, age, body-mass index, allergic status, asthma duration, ACQ-7 score at baseline, or prior use of systemic glucocorticoids 103 .
A further two replicated, double-dummy trials, the MezzoTinA-asthma studies have examined the effects of tiotropium in patients with moderate symptomatic asthma (ACQ-7 score ≥ 1.5) and persistent airflow obstruction (post-bronchodilator FEV 1 , 60-90%) despite treatment with medium-dose ICS (400-800 μg of budesonide or the equivalent) 91 . A post-hoc analysis of the PrimoTinA-asthma and MezzoTinA-asthma studies has examined whether the coprimary endpoints were influenced by serum immunoglobulin E (IgE) levels, blood eosinophil counts, or clinician judgment of allergic asthma. In addition, the influence of the continuous parameters of IgE and blood eosinophils was modelled over the whole range of values 104 . Tiotropium was found to be efficacious in improving peak and trough FEV 1 and reducing the risk of severe asthma exacerbations and asthma worsening, independent of T2 status. The effect of tiotropium on exacerbations was independent of IgE levels or eosinophil counts when analysed continuously and numerical improvements the ACQ responder An observational study of patients with asthma treated in primary care in the United Kingdom (UK) has also shown tiotropium leads to a reduction in the percentage of patients having at least one exacerbation from 37% to 27% after 1 year 105 . Tiotropium has been shown to be a cost-effective approach to asthma care, principally as a result of the reduced expenditure on exacerbations and improved quality of life 106 and the Global Initiative for Asthma (GINA) guidelines now recommend tiotropium as an add-on therapy for Steps 4 and 5 of the treatment pathway, independent of patient phenotype 107 .
Overall in adults seven trials have assessed the effect of 5 μg of tiotropium and four the effect of 2.5 μg as add on therapy to at least ICS in asthma. For some outcomes in some studies 5 μg was not superior to 2.5 μg, but taking all outcomes into account, including morning and evening peak flow results and the safety data (see below), the European Medicines Agency (EMA) and other regulators decided that 5 μg should be the recommended dose. However, in the US the Food and Drug Administration (FDA) took a different view, perhaps reflecting their caution regarding the dose of inhaled long-acting bronchodilators and decided that 2.5μg should be the recommended dose.
sAfety of tIotropIum In copd And AsthmA
When delivered via Respimat 5 µg, approximately 40% of the inhaled dose of tiotropium reaches the lungs and 33% reaches systemic circulation 108 ; similar systemic exposures and urinary excretion levels are seen with HandiHaler 109, 110 . Gastrointestinal absorption of LAMAs is low and the structure of tiotropium also prevents crossing of the blood-brain barrier, avoiding the risk of central neurologic effects 111 .
The safety profile of tiotropium in people with COPD using both the HandiHaler and the Respimat has been well characterised. In patients across all disease severities and with a range of common comorbidities there is a low incidence of adverse events 36 . Dry mouth is a predictable but relatively infrequent side effect of anticholinergics: in a meta-analysis of 16 trials the cumulative incidence of dry mouth with tiotropium was 7.4%, compared with 3.9% with ipratropium, 1.6% with salmeterol and 2.0% with placebo 33 .
Pooled analyses of clinical trials of tiotropium have shown reduced rates of cardiac adverse events and cardiovascular mortality versus placebo 36, 60 . Long-term data from UPLIFT demonstrated no increase in all-cause and cardiovascular mortality, nor any increased risk of myocardial infarction or stroke versus standard care 37 . In fact, there was a reduction in cardiac adverse events in people treated with tiotropium 112 . The Tiotropium Safety and Performance in Respimat (TIOSPIR) study also demonstrated conclusively that there was no difference in the cardiac or other safety signal between tiotropium HandiHaler and tiotropium Respimat 40 in people with COPD.
In line with previous studies, a recent study in Taiwan has shown that patients with COPD who are established on long acting bronchodilator therapy (both LABA and LAMA) are at a reduced risk of cardiovascular disease,
but it has suggested that for the first 30 days after initiation of long acting bronchodilator therapy patients may be at an increased risk 113 . This needs to be examined in other cohorts.
The safety of tiotropium in asthma has been evaluated in more than 6,000 patients as addon to ICS and ICS plus LABA, with treatment durations up to 1 year. In studies of patients with uncontrolled severe asthma including 912 patients, the incidence of adverse events was similar in the tiotropium and placebo groups and no deaths were reported 114 .
summAry
Tiotropium is an effective inhaled anti-muscarinic which improves lung function and patient reported outcomes, including health status, and reduces exacerbations in people with COPD, as well as slowing disease progression in those with GOLD grade 2 disease. In children, adolescents and adults with asthma it improves lung function and control when added to at least ICS therapy. There is no evidence of any significant adverse effects and in particular there are no cardiovascular safety concerns. It is a very important and effective therapy for people with chronic obstructive airways diseases.
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